Results 11 to 20 of about 376,488 (325)
Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway
Protein & Cell, 2018 Clinical success of the proteasome inhibitor established bortezomib as one of the most effective drugs in treatment of multiple myeloma (MM). While survival benefit of bortezomib generated new treatment strategies, the primary and secondary resistance of
Li Yang +13 more
doaj +1 more source
Clinical and Applied Thrombosis/Hemostasis, 2023 Venous thromboembolism (VTE) is a serious complication commonly experienced in cancer patients. Incidence of VTE typically brings poor prognosis as it represents the second most common cause of mortality in cancer patients just after the malignancy ...
Hussein Awada MD +9 more
doaj +1 more source
Bone Disease in Multiple Myeloma: Biologic and Clinical Implications
Cells, 2022 Multiple Myeloma (MM) is a hematologic malignancy characterized by the proliferation of monoclonal plasma cells localized within the bone marrow. Bone disease with associated osteolytic lesions is a hallmark of MM and develops in the majority of MM ...
Zachary S. Bernstein +2 more
doaj +1 more source
Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma
Antibodies, 2017 2015 was a groundbreaking year for the multiple myeloma community partly due to the breakthrough approval of the first two monoclonal antibodies in the treatment for patients with relapsed and refractory disease. Despite early disappointments, monoclonal
Shih-Feng Cho +6 more
doaj +1 more source
Haematologica, 2018 Allogeneic stem cell transplantation is a therapeutic option under dispute but nonetheless chosen with increasing frequency for patients suffering from multiple myeloma in Europe.
Jennifer Mosebach +8 more
doaj +1 more source
Extracellular Vesicles in Hematological Malignancies: From Biomarkers to Therapeutic Tools
Diagnostics, 2020 Small extracellular vesicles (EVs) are a heterogenous group of lipid particles released by all cell types in physiological and pathological states.
Jihane Khalife +2 more
doaj +1 more source
Experimental Hematology & Oncology, 2017 B cell lymphoma and multiple myeloma (MM) are the most common hematological malignancies which benefit from therapeutic monoclonal antibodies (mAbs)-based immunotherapies.
Li Zhang +4 more
doaj +1 more source
npj Precision Oncology, 2023 Optimal first-line treatment that enables deeper and longer remission is crucially important for newly diagnosed multiple myeloma (NDMM). In this study, we developed the machine learning (ML) models predicting overall survival (OS) or response of the ...
Sung-Soo Park +11 more
doaj +1 more source
The Emerging Role of Extracellular Vesicle-Associated RNAs in the Multiple Myeloma Microenvironment
Frontiers in Oncology, 2021 Multiple myeloma (MM) is a cancer of terminally differentiated plasma cells (PCs) that develop at multiple sites within the bone marrow (BM). MM is treatable but rarely curable because of the frequent emergence of drug resistance and relapse.
Jihane Khalife +4 more
doaj +1 more source